248 related articles for article (PubMed ID: 27989877)
41. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
42. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
[TBL] [Abstract][Full Text] [Related]
43. GPX4 Plays a Crucial Role in Fuzheng Kang'ai Decoction-Induced Non-Small Cell Lung Cancer Cell Ferroptosis.
Zhao YY; Yang YQ; Sheng HH; Tang Q; Han L; Wang SM; Wu WY
Front Pharmacol; 2022; 13():851680. PubMed ID: 35496303
[No Abstract] [Full Text] [Related]
44. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ
Complement Ther Med; 2014 Dec; 22(6):1010-8. PubMed ID: 25453521
[TBL] [Abstract][Full Text] [Related]
45. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
[TBL] [Abstract][Full Text] [Related]
46. Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species.
Liu BN; Yan HQ; Wu X; Pan ZH; Zhu Y; Meng ZW; Zhou QH; Xu K
Cell Biochem Biophys; 2013 May; 66(1):81-92. PubMed ID: 23111983
[TBL] [Abstract][Full Text] [Related]
47. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
48. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
[TBL] [Abstract][Full Text] [Related]
49. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D
Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804
[TBL] [Abstract][Full Text] [Related]
50. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
51. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
Xiao X; He Z; Cao W; Cai F; Zhang L; Huang Q; Fan C; Duan C; Wang X; Wang J; Liu Y
Int J Oncol; 2016 Jun; 48(6):2608-18. PubMed ID: 27082429
[TBL] [Abstract][Full Text] [Related]
52. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
53. Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib.
Ma JA; Hu C; Li W; Ren J; Zou F; Zhou D; Zou W; Wei Y; Zhou Y
Mol Med Rep; 2015 Mar; 11(3):2269-75. PubMed ID: 25395073
[TBL] [Abstract][Full Text] [Related]
54. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Loprevite M; Tiseo M; Chiaramondia M; Capelletti M; Bozzetti C; Bortesi B; Naldi N; Nizzoli R; Dadati P; Kunkl A; Zennaro D; Lagrasta C; Campanini N; Spiritelli E; Camisa R; Grossi F; Rindi G; Franciosi V; Ardizzoni A
Clin Cancer Res; 2007 Nov; 13(21):6518-26. PubMed ID: 17975165
[TBL] [Abstract][Full Text] [Related]
55. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
56. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
57. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway.
Woo JK; Choi Y; Oh SH; Jeong JH; Choi DH; Seo HS; Kim CW
Oncogene; 2012 Apr; 31(17):2187-98. PubMed ID: 21927028
[TBL] [Abstract][Full Text] [Related]
58. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Deng QF; Su B; Zhao YM; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):813-6. PubMed ID: 19173824
[TBL] [Abstract][Full Text] [Related]
59. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
60. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]